Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide

Chung Ze Wu, Dee Pei, An-Tsz Hsieh, Kun Wang, Jiunn Diann Lin, Li Hsiu Lee, Yi Min Chu, Fone Ching Hsiao, Chun Pei, Te Lin Hsia

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The traditional sulfonylureas with long half-lives have sustained stimulatory effects on insulin secretion compared to the short-acting insulin secretagogue. In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide. The design of study was randomizedcrossover. We enrolled 20 patients with new-onset type 2 diabetes (mean age, 49.3 years). Totally three FSIGTs were performed, one before and one after each of the two treatment periods as aforementioned. No significant differences in fasting plasma glucose, insulin, body mass index, blood pressure, glycated hemoglobin, or lipids were noted between the two treatments. After the repaglinide treatment, higher AIRg, lower IS, and lower SG were noted, but they did not reach statistical significance. The disposal index (DI) was also not significantly different between the two treatments. In conclusion, since non-significantly higher DI, AIRg, lower IS and SG were noted after repaglinide treatment, it might be a better treatment for diabetes, relative to gliclazide.

Original languageEnglish
Pages (from-to)411-416
Number of pages6
JournalArchives of Pharmacal Research
Volume33
Issue number3
DOIs
Publication statusPublished - Mar 2010

Fingerprint

repaglinide
Gliclazide
Insulin Resistance
Insulin
Glucose
Therapeutics
Medical problems
Short-Acting Insulin
Glycosylated Hemoglobin A
Glucose Tolerance Test
Blood pressure
Type 2 Diabetes Mellitus
Fasting

Keywords

  • Disposal index
  • Frequently sampled intravenous glucose tolerance test
  • Gliclazide
  • Insulin sensitivity
  • Repaglinide

ASJC Scopus subject areas

  • Molecular Medicine
  • Organic Chemistry
  • Drug Discovery

Cite this

Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. / Wu, Chung Ze; Pei, Dee; Hsieh, An-Tsz; Wang, Kun; Lin, Jiunn Diann; Lee, Li Hsiu; Chu, Yi Min; Hsiao, Fone Ching; Pei, Chun; Hsia, Te Lin.

In: Archives of Pharmacal Research, Vol. 33, No. 3, 03.2010, p. 411-416.

Research output: Contribution to journalArticle

Wu, Chung Ze ; Pei, Dee ; Hsieh, An-Tsz ; Wang, Kun ; Lin, Jiunn Diann ; Lee, Li Hsiu ; Chu, Yi Min ; Hsiao, Fone Ching ; Pei, Chun ; Hsia, Te Lin. / Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. In: Archives of Pharmacal Research. 2010 ; Vol. 33, No. 3. pp. 411-416.
@article{b0e9f52bd06c4f15bc1f97c440cea97e,
title = "Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide",
abstract = "The traditional sulfonylureas with long half-lives have sustained stimulatory effects on insulin secretion compared to the short-acting insulin secretagogue. In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide. The design of study was randomizedcrossover. We enrolled 20 patients with new-onset type 2 diabetes (mean age, 49.3 years). Totally three FSIGTs were performed, one before and one after each of the two treatment periods as aforementioned. No significant differences in fasting plasma glucose, insulin, body mass index, blood pressure, glycated hemoglobin, or lipids were noted between the two treatments. After the repaglinide treatment, higher AIRg, lower IS, and lower SG were noted, but they did not reach statistical significance. The disposal index (DI) was also not significantly different between the two treatments. In conclusion, since non-significantly higher DI, AIRg, lower IS and SG were noted after repaglinide treatment, it might be a better treatment for diabetes, relative to gliclazide.",
keywords = "Disposal index, Frequently sampled intravenous glucose tolerance test, Gliclazide, Insulin sensitivity, Repaglinide",
author = "Wu, {Chung Ze} and Dee Pei and An-Tsz Hsieh and Kun Wang and Lin, {Jiunn Diann} and Lee, {Li Hsiu} and Chu, {Yi Min} and Hsiao, {Fone Ching} and Chun Pei and Hsia, {Te Lin}",
year = "2010",
month = "3",
doi = "10.1007/s12272-010-0310-6",
language = "English",
volume = "33",
pages = "411--416",
journal = "Archives of Pharmacal Research",
issn = "0253-6269",
publisher = "Pharmaceutical Society of Korea",
number = "3",

}

TY - JOUR

T1 - Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide

AU - Wu, Chung Ze

AU - Pei, Dee

AU - Hsieh, An-Tsz

AU - Wang, Kun

AU - Lin, Jiunn Diann

AU - Lee, Li Hsiu

AU - Chu, Yi Min

AU - Hsiao, Fone Ching

AU - Pei, Chun

AU - Hsia, Te Lin

PY - 2010/3

Y1 - 2010/3

N2 - The traditional sulfonylureas with long half-lives have sustained stimulatory effects on insulin secretion compared to the short-acting insulin secretagogue. In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide. The design of study was randomizedcrossover. We enrolled 20 patients with new-onset type 2 diabetes (mean age, 49.3 years). Totally three FSIGTs were performed, one before and one after each of the two treatment periods as aforementioned. No significant differences in fasting plasma glucose, insulin, body mass index, blood pressure, glycated hemoglobin, or lipids were noted between the two treatments. After the repaglinide treatment, higher AIRg, lower IS, and lower SG were noted, but they did not reach statistical significance. The disposal index (DI) was also not significantly different between the two treatments. In conclusion, since non-significantly higher DI, AIRg, lower IS and SG were noted after repaglinide treatment, it might be a better treatment for diabetes, relative to gliclazide.

AB - The traditional sulfonylureas with long half-lives have sustained stimulatory effects on insulin secretion compared to the short-acting insulin secretagogue. In this study, we used the frequently sampled intravenous glucose tolerance test (FSIGT) to evaluate the insulin sensitivity (IS), glucose sensitivity (SG), and acute insulin response after glucose load (AIRg) after 4 months treatment with either gliclazide or repaglinide. The design of study was randomizedcrossover. We enrolled 20 patients with new-onset type 2 diabetes (mean age, 49.3 years). Totally three FSIGTs were performed, one before and one after each of the two treatment periods as aforementioned. No significant differences in fasting plasma glucose, insulin, body mass index, blood pressure, glycated hemoglobin, or lipids were noted between the two treatments. After the repaglinide treatment, higher AIRg, lower IS, and lower SG were noted, but they did not reach statistical significance. The disposal index (DI) was also not significantly different between the two treatments. In conclusion, since non-significantly higher DI, AIRg, lower IS and SG were noted after repaglinide treatment, it might be a better treatment for diabetes, relative to gliclazide.

KW - Disposal index

KW - Frequently sampled intravenous glucose tolerance test

KW - Gliclazide

KW - Insulin sensitivity

KW - Repaglinide

UR - http://www.scopus.com/inward/record.url?scp=77953634464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953634464&partnerID=8YFLogxK

U2 - 10.1007/s12272-010-0310-6

DO - 10.1007/s12272-010-0310-6

M3 - Article

C2 - 20361306

AN - SCOPUS:77953634464

VL - 33

SP - 411

EP - 416

JO - Archives of Pharmacal Research

JF - Archives of Pharmacal Research

SN - 0253-6269

IS - 3

ER -